StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Non-GAAP Research and development expenses by Quarter

Non-GAAP Research and development expenses ($M) ($M)

QuarterlyAnnual

Gilead Sciences Non-GAAP Research and development expenses: $1,764M in Q2 2026, up 18.3% from a year earlier. That is the highest of the 39 quarters on record here.

Latest, Q2 2026
1,764
Period ended Jun 30, 2026
Change on a year earlier
+18.3%
1,491 in Q2 2025
History
39 quarters
Since Q4 2016
Sources
34
Documents cited below

Where the Q2 2026 figure comes from

“|| Research and development expenses | 1,764 | 1,491 | 3,136 | 2,870”

Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗

Reported in Form 8-K Reconciliation of GAAP to Non-GAAP Financial Information.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP Research and development expenses ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20261,764+18.3%Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 20261,372-0.5%Form 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2025Dec 31, 20251,584-3.5%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2025Sep 30, 20251,346-3.5%Form 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 20251,491+10.4%Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 20251,379-9.3%Form 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2024Dec 31, 20241,641+16.5%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2024Sep 30, 20241,395-4.3%Form 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 20241,351-4.0%Form 8-K (exhibit991earningspressrel.htm, filed 2025-08-07) ↗
Q1 2024Mar 31, 20241,520+5.0%Form 8-K (exhibit991earningspressrel.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 20231,408-9.0%Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗
Q3 2023Sep 30, 20231,457+26.8%Form 8-K (exhibit991earningspressrel.htm, filed 2024-11-06) ↗
Q2 2023Jun 30, 20231,407+27.7%Form 8-K (exhibit991earningspressrel.htm, filed 2024-08-08) ↗
Q1 2023Mar 31, 20231,447+22.8%Form 8-K (exhibit991earningspressrel.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 20221,548+14.0%Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗
Q3 2022Sep 30, 20221,149+4.4%Form 8-K (exhibit991earningspressrel.htm, filed 2023-11-07) ↗

Breakdown

What makes up non-GAAP Research and development expenses

Cite this data

StockData. (2026). Gilead Sciences Non-GAAP Research and development expenses ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rd-nongaap-tot

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.